Treatment with Tafinlar in combination with Mekinist showed what researchers described as “considerable efficacy” among ...

A 22-month-old girl, Sophia Watson, is in urgent need of life-saving treatment for a tumor, but an insurance dispute has left her family without coverage.

Day One Biopharma's OJEMDA FDA approval for pediatric glioma, but market concerns remain. Check out why I rate DAWN stock as ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall ...

competing with Novartis’ Tafinlar-Mekinist duo, which boasts a second-line tumor-agnostic indication for any solid tumors that have a BRAF V600E mutation.

Other growth drivers, such as Jakavi and Tafinlar + Mekinist, have likely witnessed an increase in demand. However, generic competition for Tasigna has likely affected sales, as in the previous ...

Strong performances by Jakavi (up 13% to $487 million) and Tafinlar + Mekinist (up 10% to $527 million) also boosted the top line. Pluvicto (prostate cancer) raked in sales of $351 million ...

Deliver returns: Continuing to embed operational excellence and deliver improved financials. Novartis remains disciplined and shareholder-focused in our approach to capital allocation, with ...

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the fourth quarter of 2024. Core earnings ...